T1	Participants 89 115	advanced pancreatic cancer
T2	Participants 364 390	advanced pancreatic cancer
T3	Participants 535 626	patients with advanced pancreatic adenocarcinoma previously untreated with systemic therapy
T4	Participants 980 1027	Six hundred eighty-eight patients were enrolled
T5	Participants 1898 1924	advanced pancreatic cancer
